Prostate cancer is the most commonly diagnosed cancer affecting men in the United States.
The prostate is a hormone-dependent gland in which androgen hormones testosterone and …

Human aldo-keto reductases (AKRs) catalyze the NADPH-dependent reduction of carbonyl
groups to alcohols for conjugation reactions to proceed. They are implicated in resistance to …

Although DNA methylation is a key regulator of gene expression, the comprehensive
methylation landscape of metastatic cancer has never been defined. Through whole …

Background Darolutamide is a structurally unique androgen-receptor antagonist that is
under development for the treatment of prostate cancer. We evaluated the efficacy of …

Tumor mutational burden and heterogeneity has been suggested to fuel resistance to many
targeted therapies. The cytosine deaminase APOBEC proteins have been implicated in the …

Background The androgen-receptor isoform encoded by splice variant 7 lacks the ligand-
binding domain, which is the target of enzalutamide and abiraterone, but remains …

Background Enzalutamide is an oral androgen-receptor inhibitor that prolongs survival in
men with metastatic castration-resistant prostate cancer in whom the disease has …

Metastatic castration-resistant prostate cancer (PC) is the final stage of PC that acquires
resistance to androgen deprivation therapies (ADT). Despite progresses in understanding of …

Background Enzalutamide (formerly called MDV3100) targets multiple steps in the androgen-
receptor–signaling pathway, the major driver of prostate-cancer growth. We aimed to …

Background Abiraterone acetate improved overall survival in metastatic castration-resistant
prostate cancer at a preplanned interim analysis of the COU-AA-301 double-blind, placebo …